Cipla announces Q2 FY22 results Growth momentum across core therapies and markets continue and sustained cost control drives EBITDA margin of 22.2% Income from Operations - INR 5,520 Cr, 10% YoY EBITDA - INR 1,226 Cr, 4% YoY PAT - INR 711 Cr, 7% YoY Key highlights of the quarter: One India: Overall business grew by 16% YoY on high FY21 base led by sustained volume traction across core therapies; covid portfolio contribution normalising in-line with expectations SAGA: Continued market beating growth in South Africa private business; SAGA grew 8% YoY in USD terms US business: Reported USD 142Mn revenue at multi-quarter high; Steady momentum in core products offsetting price erosion in rest of the portfolio R&D; investments stand at INR 274 crore; Priority projects spends on track Continued healthy net cash positive position led by growth in operating profitability and prudent working capital management; Prepaid USD 137.5Mn outstanding InvaGen acquisition debt during the quarter “I am pleased to see the strong momentum in core therapies across our branded markets and sustained cost control leading to 10% revenue growth and 22.2% EBITDA margin for the quarter, offsetting price erosion and normalising covid contribution. In India, we continue to drive strong performance led by sustained volume traction despite a high FY21 base. Our collaboration with Eli Lily for their diabetes products helps us further strengthen our endeavour of creating access to innovative medicines in-line with the One-India strategy. The US business also witnessed healthy run rate driven by core portfolio and desired traction in respiratory franchise across Albuterol and Arformoterol. International markets rebounded in-line with expectations despite continuing geopolitical challenges. Featuring in the Forbes World’s Best Employers 2021, affirms our commitment to promote a positive and inclusive culture and sustained efforts to build a future fit organisation” Umang Vohra MD and Global CEO, Cipla Ltd Result PDF
Conference Call with Cipla Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.